MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 30, 2005; DOI: 10.1124/mol.105.014795


0026-895X/05/6806-1510-1523$20.00
Mol Pharmacol 68:1510-1523, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.105.014795v1
68/6/1510    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hansen, K. B.
Right arrow Articles by Bräuner-Osborne, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hansen, K. B.
Right arrow Articles by Bräuner-Osborne, H.

Tweaking Agonist Efficacy at N-Methyl-D-aspartate Receptors by Site-Directed Mutagenesis{boxs}

Kasper B. Hansen, Rasmus P. Clausen, Esben J. Bjerrum, Christian Bechmann, Jeremy R. Greenwood, Caspar Christensen, Jesper L. Kristensen, Jan Egebjerg, and Hans Bräuner-Osborne

Department of Medicinal Chemistry, Danish University of Pharmaceutical Sciences, Copenhagen, Denmark (K.B.H., R.P.C., E.J.B., C.B., J.R.G., C.C., J.L.K., H.B.-O.); and Department of Molecular Neurobiology, H. Lundbeck A/S, Copenhagen, Denmark (K.B.H., C.B., J.E.)

The structural basis for partial agonism at N-methyl-D-aspartate (NMDA) receptors is currently unresolved. We have characterized several partial agonists at the NR1/NR2B receptor and investigated the mechanisms underlying their reduced efficacy by introducing mutations in the glutamate binding site. Key residues were selected for mutation based on ligand-protein docking studies using a homology model of NR2B-S1S2 built from the X-ray structure of NR1-S1S2 in complex with glycine. Wild-type and mutant forms of NR2B were coexpressed with NR1 in Xenopus laevis oocytes and characterized by two-electrode voltage-clamp electrophysiology. By combining mutagenesis of residues His486 or Val686 with activation by differently substituted partial agonists, we introduce varying degrees of steric clash between the ligand and the two binding domains S1 and S2. In cases where ligand-protein docking predicts increased steric clashes between agonists and the residues forming the S1-S2 interface, the agonists clearly show decreased relative efficacy. Furthermore, we demonstrate that the mutation S690A affects both potency and efficacy in an agonist-specific manner. The results indicate that essential residues in the ligand binding pocket of NR2B may adopt different conformations depending on the agonist bound. Together, these data indicate that agonist efficacy at the NR2B subunit can be controlled by the extent of steric clashes between the agonist and the ligand binding domains and by ligand-dependent arrangements of residues within the binding pocket.


Received May 17, 2005; accepted August 30, 2005

Address correspondence to: Hans Bräuner-Osborne, Department of Medicinal Chemistry, Danish University of Pharmaceutical Sciences, Universitetsparken 2, DK-2100 Copenhagen, Denmark. E-mail: hbo{at}molpharm.net




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. L. Blanke and A. M. J. VanDongen
Constitutive Activation of the N-Methyl-D-aspartate Receptor via Cleft-spanning Disulfide Bonds
J. Biol. Chem., August 1, 2008; 283(31): 21519 - 21529.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
P. E. Chen, M. T. Geballe, E. Katz, K. Erreger, M. R. Livesey, K. K. O'Toole, P. Le, C. J. Lee, J. P. Snyder, S. F. Traynelis, et al.
Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes
J. Physiol., January 1, 2008; 586(1): 227 - 245.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
K. Erreger, M. T. Geballe, A. Kristensen, P. E. Chen, K. B. Hansen, C. J. Lee, H. Yuan, P. Le, P. N. Lyuboslavsky, N. Micale, et al.
Subunit-Specific Agonist Activity at NR2A-, NR2B-, NR2C-, and NR2D-Containing N-Methyl-D-aspartate Glutamate Receptors
Mol. Pharmacol., October 1, 2007; 72(4): 907 - 920.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
P. Naur, K. B. Hansen, A. S. Kristensen, S. M. Dravid, D. S. Pickering, L. Olsen, B. Vestergaard, J. Egebjerg, M. Gajhede, S. F. Traynelis, et al.
Ionotropic glutamate-like receptor {delta}2 binds D-serine and glycine
PNAS, August 28, 2007; 104(35): 14116 - 14121.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
D. J. A. Wyllie, A. R. Johnston, D. Lipscombe, and P. E. Chen
Single-channel analysis of a point mutation of a conserved serine residue in the S2 ligand-binding domain of the NR2A NMDA receptor subunit
J. Physiol., July 15, 2006; 574(2): 477 - 489.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics